Aegle Therapeutics is focused on extracellular vesicle therapy, an emerging therapeutic platform in the area of regenerative medicine. We are developing a series of novel therapeutics using extracellular vesicles secreted by stem cells isolated by our proprietary process. Aegle is focused on developing extracellular vesicle therapy to treat burns and chronic pressure ulcers as the first step in the therapeutic development of its technology.
Aegle has demonstrated that extracellular vesicles, including exosomes, promote cellular proliferation and migration, angiogenesis and neuronal regeneration. In porcine full-thickness wound models, Aegle’s extracellular vesicle therapy resulted in rapid wound healing as well as nerve growth, new blood vessel formation and evidence of dermal regeneration (scarring reduction).
In addition to wounds, Aegle believes that extracellular vesicles secreted by stem cells and isolated using Aegle’s process will produce a highly effective therapy in many other areas of tissue regeneration including the rare children’s disease Recessive Dystrophic Epidermolysis Bullosa, orthopedic injury, cardiovascular disease and others.
Aegle plans to file two INDs in 2016 for the treatment of burns and chronic pressure ulcers.